Coumarins hinged directly on benzimidazoles and their ribofuranosides to inhibit hepatitis C virus

A new compound library that contained 20 hinged benzimidazole–coumarin hybrids and their β-d-ribofuranosides was established. The anti-hepatitis C virus (HCV) activity of all novel coumarin derivatives, which were obtained by use of organic synthetic methods, was tested. Two of these hybrids exhibited appealing EC50 values of as low as 3.0 and 5.5 μM. The best selectivity index was 14. The incorporation of a d-ribofuranose into the hinged hybrids provided the corresponding nucleosides with the β configuration, one of which inhibited HCV replication with an EC50 value of 20 μM. Additionally, the structure–activity relationship is elucidated on the basis of the functional groups that were attached to the nuclei of benzimidazole, coumarin, and ribofuranose of the hybrids.

A compound library containing 20 new hybrids was established by chemical synthesis. Three hybrids inhibited HCV replication with EC50 values as low as 3.0, 5.5, and 20 μM.Figure optionsDownload as PowerPoint slideHighlights
► A new compound library containing 20 hinged benzimidazole–coumarin hybrids was established.
► These compounds inhibited HCV replication with EC50 values as low as 3.0 μM.
► A structure–activity relationship with five guidelines is illustrated.